Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Heparins Outperform DOACs and FXII/FXI Inhibitors in Preventing Thrombin Generation: JTH Study
JTH/ LinkedIn
Sep 2, 2025, 13:39

Heparins Outperform DOACs and FXII/FXI Inhibitors in Preventing Thrombin Generation: JTH Study

Journal of Thrombosis and Haemostasis (JTH) shared an insightful post on LinkedIn:

“Effect of heparins, direct oral anticoagulants, and factor XII/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study

This in vitro catheter-initiated thrombin generation model compared heparins, DOACs, and emerging FXII/FXI inhibitors. Heparins were the most effective, with UFH completely suppressing thrombin generation at clinically relevant concentrations. DOACs and fondaparinux showed limited efficacy, while FXII/FXI inhibitors (asundexian, milvexian, garadacimab, abelacimab) did not adequately prevent coagulation on artificial surfaces. Results align with clinical observations, reinforcing UFH as the gold standard in invasive endovascular procedures.”

Read the full article here:

Article: Effect of heparins, direct oral anticoagulants, and factor XII/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study

Authors: Michael Hardy, Henri Thonon, Jonathan Douxfils, Julie Vassart, Isabelle Gouin–Thibault, Sarah Lessire, Thomas Lecompte, Francois

Stay updated with Hemostasis Today.

anticoagulants catheter thrombosis DOACs endovascular Francois FXI inhibitors FXII inhibitors Health Hematology Hemostasis Today Henri Thonon heparins Isabelle Gouin–Thibault Jonathan Douxfils JTH Julie Vassart Medicine Michael Hardy Sarah Lessire Thomas Lecompte Thrombin Generation
NewsFeed